CAR-T Cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy is a form of cellular immunotherapy in which a patient's T cells are modified to recognize and attack cancer cells.

T cells are usually collected from the patient's blood and genetically engineered in a laboratory to express a chimeric antigen receptor (CAR). The CAR is designed to recognize a specific target on cancer cells, such as CD19 in certain B-cell cancers or BCMA in multiple myeloma. The modified cells are expanded and then infused back into the patient, where they can recognize and attack cancer cells carrying the target.

CAR-T therapy is currently used mainly for certain blood cancers and has created new treatment options for some patients with relapsed or refractory leukemia, lymphoma, and multiple myeloma. CAR-T therapy is also being studied in solid tumors, although its role in these cancers remains investigational.

CAR-T therapy is not appropriate for every patient with cancer. Eligibility depends on the cancer type, whether the cancer cells express a suitable target, previous treatments, current disease status, organ function, and overall health.

CAR-T therapy is currently used primarily for certain B-cell malignancies and multiple myeloma. For example, CD19-directed CAR-T therapies are used for selected patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphomas, while BCMA-directed CAR-T therapies are used mainly for multiple myeloma. As research continues, additional targets and disease settings are being explored.

The timing of CAR-T therapy also varies. Some patients receive CAR-T after several previous treatments, while in certain diseases it may now be considered earlier in the relapsed or refractory setting. The decision requires an individualized assessment.

CAR-T therapy is more than a single cell infusion. It is a multistep treatment process that includes evaluation, cell collection, manufacturing, conditioning therapy, infusion, and close monitoring afterward.

Before treatment, the healthcare team evaluates the patient's disease status, tumor burden, infections, and the function of major organs such as the heart, lungs, liver, and kidneys.

If the patient is eligible, T cells are collected from the blood through a procedure called leukapheresis. The cells are then genetically modified and expanded in a laboratory so they can recognize a specific tumor antigen. Manufacturing takes time, and some patients with rapidly progressing disease may need bridging therapy while waiting for the CAR-T cells to be prepared.

Before CAR-T infusion, patients usually receive several days of lymphodepleting chemotherapy. This reduces certain immune cells and helps create an environment in which the infused CAR-T cells can expand and function.

The CAR-T cells are then infused intravenously. Patients are monitored closely afterward for changes in temperature, blood pressure, oxygen levels, neurologic status, blood counts, and other signs that may indicate treatment-related complications.

After CAR-T cell infusion, treatment response is assessed at different time points using bone marrow examinations, imaging, measurable residual disease (MRD) testing, tumor markers, or other disease-specific tests.

For example, response in leukemia may be evaluated using bone marrow and MRD testing. PET-CT is commonly used to assess response in lymphoma, while multiple myeloma may be monitored using bone marrow findings, monoclonal protein levels, free light chains, and other tests.

Some patients can achieve deep and durable remissions after CAR-T therapy, but treatment does not eliminate the possibility of relapse. Long-term follow-up is needed to monitor the cancer, blood count recovery, immune function, and infection risk.

After infusion, CAR-T cells can become highly activated and expand rapidly, which may cause immune-related toxicities. Two of the most important complications are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

CRS commonly causes fever and may also lead to low blood pressure or low oxygen levels. Severity varies widely, and most cases occur relatively early after CAR-T infusion. Close monitoring and treatment are based on the severity of the reaction.

ICANS may cause changes in attention or consciousness, difficulty speaking or writing, drowsiness, tremor, or other neurologic symptoms. In severe cases, seizures or other serious neurologic complications can occur, so regular neurologic assessment is an important part of post-infusion monitoring.

CAR-T therapy may also cause prolonged low blood cell counts and an increased risk of infection. CD19-directed CAR-T therapy can result in B-cell depletion and low immunoglobulin levels, while BCMA-directed therapy can also affect normal immune function. Some patients therefore require immunoglobulin monitoring, infection prevention, or other supportive care.

Rare but potentially serious immune complications, including immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), may also occur. The specific risks vary according to the CAR-T product, cancer type, tumor burden, and individual patient factors.